Skip to Content
Morningstar
Get 14 Days Free

BioNTech SE BNTX

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Raising Our BioNTech FVE to $139 on Strong COVID-19 Vaccine Revenue and Flu Prospects

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We've raised our fair value estimate for BioNTech to $139 per share from $124 following first-quarter results, as we've raised our COVID-19 vaccine revenue projections slightly for the year and added potential revenue for an mRNA-based influenza vaccine beginning in 2024, but also raised our tax rate assumptions for the firm.

Read Full Analysis

Company Profile

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact
An der Goldgrube 12
Mainz, D-55131, Germany
T +49 613190840
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type —
Employees 1,941

Related

Market Update
Are Vaccinemakers Attractive Today?
Here are a few drugmakers we like that are undervalued.
Sachin Nagarajan
Stock Analyst Update
BioNTech Reports Strong Vaccine Revenue, Flu Prospects
We've raised our fair value estimate for BioNTech to $139 per share.
Karen Andersen
Stock Analyst Update
Waiving Vaccine IP Doesn't Affect Market Assessment
Following the news the Biden administration supports a proposed waiver on intellectual property protection for COVID-19 vaccines, we are not changing our FVEs to COVID-19 vaccine firms.
Karen Andersen
Stock Strategist Industry Reports
Moderna Dominates COVID-19 Vaccine Manufacturers, at Least for Now
The global COVID-19 vaccine market is currently dominated by mRNA firms, but competitors are gaining strength.
Karen Andersen
Stock Strategist Industry Reports
U.S. Herd Immunity Could Be Coming by End of June
Limited vaccine supply in other countries could make global immunity tougher to achieve, though.
Karen Andersen
Stock Strategist
Moderna's Innovation Still Building a Moat
The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.
Karen Andersen
Stock Analyst Update
Why We Increased Our BioNTech Fair Value Estimate
Here is what our new COVID-19 vaccine forecast revealed about the no-moat company.
Karen Andersen
Stock Analyst Update
BioNTech Reports Solid Fourth-Quarter Results
We intend to modestly raise our fair value estimate based on this near-term strength as its COVID-19 vaccine was the highlight of the quarter.
Damien Conover
Fund Spy
How the Biggest and Best Funds Fared After the Crash
A look at how some notable U.S. equity funds have navigated the market's style and size reversals over the past year.
Alec Lucas
Special Report
Special Report: Investing in Strange Times
We reflect on lessons learned--and reaffirmed--over the past year of investing amid market uncertainty.
Jerry Kerns
Market Update
These Sectors Performed Best and Worst in the Pandemic
We look at the industries for those most affected by social-distancing and stay-at-home orders.
Sachin Nagarajan
Stock Analyst Update
J&J Releases COVID-19 Vaccine Data
The data doesn't significantly alter our valuation or U.S. herd immunity forecast.
Karen Andersen
Commentary
The Week Ahead: Google, Amazon, and Pfizer to Report Earnings
Other big names in the energy and healthcare sectors are on the calendar for the week ahead as well.
Carole Hodorowicz
Stock Strategist Industry Reports
COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover
However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.
Karen Andersen
Stock Strategist Industry Reports
COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic
Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen
Stock Analyst Update
FDA Supports EUA for Pfizer-BioNTech’s COVID-19 Vaccine
The FDA provided emergency use authorization, or EUA, for Pfizer and partner BioNTech’s COVID-19 vaccine BNT162b2 on Dec. 11. However, we are not changing our fair value for either Pfizer or BioNTech as the EUA was largely expected.
Damien Conover
Stock Analyst Update
Pfizer/BioNTech Report 95% Efficacy Rate for Vaccine
After reporting strong final data, we expect emergency authorization of Pfizer and BioNTech's vaccine by early December.
Damien Conover
Commentary
Finally Time for Value Stocks to Shine?
As the pathway to economic normalization in 2021 becomes clear, the market has begun to favor value stocks over growth stocks.
David Sekera
Stock Analyst Update
Maintaining Our FVE For BioNTech After Q3 Results
Details around its COVID-19 vaccine program were the highlight of Q3, but other drugs in the pipeline also demonstrated decent progress.
Karen Andersen
Stock Analyst Update
Pfizer and BioNTech Report Strong COVID-19 Vaccine Data
With the vaccine’s efficacy over 90% and no major safety issues observed, we believe Pfizer and BioNTech's vaccine is set up for emergency use in late 2020, followed by full approval in 2021 pending supportive final data.
Damien Conover

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.